Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Liabilities (2016 - 2025)

Historic Total Liabilities for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $22.8 million.

  • RedHill Biopharma's Total Liabilities rose 375.18% to $22.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.8 million, marking a year-over-year increase of 375.18%. This contributed to the annual value of $22.7 million for FY2024, which is 833.25% up from last year.
  • Per RedHill Biopharma's latest filing, its Total Liabilities stood at $22.8 million for Q2 2025, which was up 375.18% from $22.7 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Total Liabilities ranged from a high of $203.2 million in Q3 2022 and a low of $2.6 million during Q4 2022
  • For the 5-year period, RedHill Biopharma's Total Liabilities averaged around $101.7 million, with its median value being $112.0 million (2021).
  • Per our database at Business Quant, RedHill Biopharma's Total Liabilities tumbled by 9847.78% in 2022 and then soared by 69977.13% in 2023.
  • Over the past 5 years, RedHill Biopharma's Total Liabilities (Quarter) stood at $172.3 million in 2021, then tumbled by 98.48% to $2.6 million in 2022, then soared by 699.77% to $21.0 million in 2023, then increased by 8.33% to $22.7 million in 2024, then grew by 0.27% to $22.8 million in 2025.
  • Its Total Liabilities stands at $22.8 million for Q2 2025, versus $22.7 million for Q4 2024 and $22.0 million for Q2 2024.